shallb5817c9194

April 8, 2024 Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24 Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated   Results support initiation of the Phase 3 FORTITUDE-HCM clinical […]

March 25, 2024 Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24) Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete; Phase 3 to be initiated in the 2H 2024   BOSTON, Mass., March 25, 2024 –

November 12, 2023 Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement in dobutamine stress-induced ischemic left ventricular (LV) dysfunction compared

November 7, 2023 Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared to placebo, in a robust functional cardiopulmonary exercise test (CPET) measure

August 16, 2023 Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023   Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM in non-obstructive hypertrophic cardiomyopathy and interim data from IMPROVE-DiCE in

June 5, 2023 Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy Enrollment exceeded expectations, thus highlighting the large unmet need in non-obstructive hypertrophic cardiomyopathy   IMPROVE-HCM topline data expected in 4Q 2023   Topline Phase 2 data from the IMPROVE-ISCHEMIA clinical trial in Stable Angina  also

May 17, 2023 Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect BOSTON, Mass., May 17, 2023 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that Anne Prener, M.D., Ph.D., president and chief executive officer, Jai Patel, MRCP(UK), chief medical officer, and Komal

January 9, 2023 Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction Phase 2 trials underway with ninerafaxstat in three cardiovascular indications; multiple data read-outs expected in 2023   BOSTON, Mass., January 9, 2023 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company

December 5, 2022 Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy BOSTON, Mass., December 5, 2022 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that Martin Maron, M.D., director of HCM

October 10, 2022 Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase BOSTON, Mass., October 10, 2022 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced that Anne Prener, M.D., Ph.D., president and chief executive officer, Jai Patel, MRCP(UK), chief medical officer, and Komal Joshi,